Rivaroxaban for treatment of pediatric venous thromboembolism: An Einstein-Jr phase 3 dose-exposure-response evaluation

G. Young*, A.W.A. Lensing, P. Monagle, C. Male, K. Thelen, S. Willmann, J.S. Palumbo, R. Kumar, I. Nurmeev, K. Hege, F. Bajolle, P. Connor, H.L. Hooimeijer, M. Torres, A.K.C. Chan, G. Kenet, S. Holzhauer, A. Santamaria, P. Amedro, J. Beyer-WestendorfI. Martinelli, M.P. Massicotte, W.T. Smith, S.D. Berkowitz, S. Schmidt, V. Price, M.H. Prins, D. Kubitza, EINSTEIN-Jr Phase 3 Investigators

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Rivaroxaban for treatment of pediatric venous thromboembolism: An Einstein-Jr phase 3 dose-exposure-response evaluation'. Together they form a unique fingerprint.

Keyphrases

INIS

Pharmacology, Toxicology and Pharmaceutical Science